Medical management of gastroesophageal reflux disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 1, 2007, Pages 39-47

  Ferguson, Dawn D ^a   DeVault, Kenneth R ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Esophagitis; Gastroesophageal reflux disease; GERD; Proton pump inhibitors

Indexed keywords

ALGINIC ACID; ANTACID AGENT; BACLOFEN; BETHANECHOL; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIDAZOLE; LANSOPRAZOLE; MACROLIDE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; TEGASEROD;

ATROPHIC GASTRITIS; CARDIOTOXICITY; CLINICAL TRIAL; DIET RESTRICTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; ENZYME INHIBITION; ESOPHAGITIS; FATIGUE; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEARTBURN; HUMAN; HYPERGASTRINEMIA; HYPERPROLACTINEMIA; INFECTION SENSITIVITY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; OBESITY; PARKINSONISM; PEPTIC ULCER; PREGNANCY; PREVALENCE; RESTLESSNESS; REVIEW; SALIVATION; SEIZURE; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH CARCINOID; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

ESOPHAGOGASTRIC JUNCTION; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 33846033213     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.1.39     Document Type: Review

References (77)

1. LOCKE III GR, TALLEY NJ, FETT SL et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, MN. Gastroenterology (1997) 112:1448-1456.
2. BRETAGNE JF, HONNORAT C, RICHARD-MOLARD B et al.: Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment. Pharmacol. Ther. (2006) 23:607-616.
3. MORAES-FILHO JP, CHINZON D, EISIG JN et al.: Prevalence of heartburn and gastroesophapeal reflux disease in the urban Brazilian population. Arquivos de Gastroenterologica (2005) 42(2):122-127.
4. FUJIWARA Y, HIGUCHI K, SHIBA M et al.: Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J. Gastroenterol. Hepatol. (2005) 20(1):26-29.
5. CHO Y, CHOI M, JEONG J et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am. J. Gastrenterol. (2005) 100(4):747-753.
6. JAFRI N, FAFRI W, YAKOOB J et al.: Perception of gastroesophageal reflux disease in urban population in Pakistan. J. Coll. Physicians Surg. Pak. (2005) 15(9):532-534.
7. ANDERSEN LI, JENSEN G: Prevalence of benign esophageal disease in the Danish population with special reference to pulmonary disease. J. Intern. Med. (1989) 1989:393-401.
8. RONKAINEN J, STORSKRUBB T, JOHANSSON SE et al.: Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 129:2101-2103.
9. GOODMAN C, CRONIN K, GEMMEN E et al.: The burden of gstrointestinal diseases. Bethesda (MD). American Gastroenterological Association (2001).
10. REVICKI DA, WOOD M, MATON PN et al.: The impact of gastroesophageal reflux disease on health-retated quality of life. Am. J. Med. (1998) 104:252-258.
11. JOHNSSON F, WEYWADT L, SOLHAUG JH et al.: One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand. J. Gastroenterol. (1998) 33:15-20.
12. NUMANS ME, LAU J, DeWITT NJ et al.: Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. A meta-analysis of diagnostic test characteristics. Ann. Intern. Med. (2004) 140:518-527.
13. SAMPLINER RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barretes Esophagus. Am. J. Gastroenterol. (2002) 97(8):1888-1895.
14. FRANSEN GA, JANSSEN MJ, MURIS JW et al.: Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment. Pharmacol. Ther (2004) 20:1045-1052.
15. FASS R, FENNERTY B, VAKIL N: Non-erosive reflux disease. Current concepts and dilemmas. Am. J. Gastroenterol. (2001) 96:303-314.
16. DEVAULT KR, CASTELL DO: Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol (1995) 155:2165-2173.
17. GERSON LB, ROBBINS AS, GARBER A et al.: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am. J. Gastreonterol. (2000) 95:395-407.
18. CONSENSUS GUIDELINE: Dyspepsia: Management of dyspepsia in adults in primary care. National Institute for Clinical Excellence (2004) Clinical Guideline 17.
19. JOHNSON LF, DEMEESTER TR: Evaluation of elevation of the head of the bed, bethanechol and antacid foam tablets on gastroesophageal reflux. Dig. Dis. Sci. (1981) 26:673-680.
20. STANCIU C, BENNET JR: Effects of posture on gastroesophageal reflux. Digestion (1977) 15:104-109.
21. MEYERS WF, HERBST JJ: Effectiveness of positioning therapy for gastroesophageal reflux. Pediatrics (1982) 69:768-772.
22. WARING JP EASTWOOD TF, AUSTIN JM et al.: The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am. J. Gastroenterol. (1989) 84:1076-1078.
23. BECKER DJ, SINCLAIR J, CASTELL DO et al.: A comparison of high and low fat meals on postprandial esophageal acid exposure. Am. J. Gastroenterol. (1989) 84:782-786.
24. HAMPEL H, ABRAHAM NS, EL-SERAG HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Int. Med. (2005) 143:199-211.
25. MURPHY DW, CASTELL DO: Chocolate and heartburn: Evidence of increased esophageal acid exposure after chocolate ingestion. Am. J. Gastroenterol. (1988) 93:633-636.
26. SIGMUND CJ, MCNALLY EF: The action of a carminative on the lower esophageal sphincter. Gastroenterology (1969) 56:13-18.
27. ALLEN ML, MELLOW MH, ROBINSON MG et al.: The effect of raw onions on acid reflux and reflux symptoms. Am. J. Gastroenterol (1990) 85:377-380.
28. PFEIFFER BW, PEHL C, SCHMIDT T et al.: Effect of decaffeination of coffeee or tea on gastro-oesophageal reflux. Aliment. Pharmacol. Ther. (1994) 8:283-287.
29. PEHL C, WENDL B, PFEIFFER A et al.: Low-proof alcoholic beverages and gastroesophageal reflux. Dig. Dis. Sci. (1993) 38:93-96.
30. GROVE O, BEKKER C, JEPPE-HANSEN MG et al.: Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand. J. Gastroenterol (1985) 20:457-461.
31. WEBERG R, BERSTAD A: Symptomatic effect of low-dose antacid regimen in reflux oesophagitis. Scand. J. Gastroenterol. (1989) 24:401-406.
32. FAAIJ R, VAN GERVEN J, JOLIVET-LANDREAU I et al.: Onset of action during on-demand treatment with Maalox suspension or low-dose ranitidine for heartburn. Aliment. Pharmacol. Ther. (1999) 13:1605-1610.
33. CHATFIELD S: A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr. Med. Res. Opin. (1999) 15:152-159.
34. SMART HL, ATKINSON M: Comparison of a dimethicone/antacid (Asilone gel) with an alginate/antacid (Gaviscon liquid) in the management of reflux oesophagitis. J. R. Soc. Med. (1990) 80:554-556.
35. CASTELL DO, DALTON CB, BECKER D et al.: Alginic acid decreases postprandial upright gastroesophageal reflux: comparison with equal-strength antacid. Dig. Dis. Sci. (1992) 37:589-593.
36. WASHINGTON N, PARKER MA, STEELE RJ et al.: Time to onset of action of sodium alginate, rantidine, omeprazole and water based on oesophageal PH. Gastroenterology (1999) 116-Abstr. A350.
37. JOHANNESSEN T, KRISTENSEN P: On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets. Clin. Ther. (1997) 19:73-81.
38. KAHRILAS PJ: Gastroesophageal reflux disease. JAMA (1996) 276:983-988.
39. KAHRILAS PJ, FENNERTY MB, JOELSSON B: High- versus standard-dose ranitidine for control of heartbun in poorly responsive acid reflux disease: a prospective, controlled trial. Am. J. Gastroenterol. (1999) 94:92-97.
40. WILLIAMS MP, POUNDER MR: Review article: the pharmacology of rabeprazole. Aliment. Pbarmacol. Ther. (1999) 13(Suppl. 3):3-10.
41. HUBER R, KOH B, SACHS G et al.: Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment. Pharmacol. Ther. (1995) 9:363-378.
42. MATON PN: Omeprazole. New Engl. J. Med. (1991) 324:965-975.
43. CHIBA N, DE GARA CJ, WILKINSON JM et al.: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798-810.
44. VAKIL N, FENNERTY MB: Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment. Pharmacol. Ther. (2003) 18:559-568.
45. KLOK RM, POSTMA MJ, BAN HOURT BA, BROWERS BJ: Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment. Pharmacol. Ther. (2003) 17:1237-1245.
46. HELLSTORM PM, VITOLS S: The choice of proton pump inhibitor: does it matter? Basic Clin. Pharmacol. Toxicol. (2004) 94:106-111.
47. HATLEBAKK JG, KATZ PO, KUO B et al.: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment. Pharmacol. Ther (1998) 12:1235-1240.
48. MINER P, KATZ PO, CHEN Y, SOSTEK M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover trial. Am. J. Gastroenterol. (2003) 98:2616-2620.
49. KATZ PO, CASTELL DO, CHEN Y, ANDERSSON T, SOSTECK MB: Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment. Pharmacol. Ther. (2004) 20:399-406.
50. HOWDEN CW: Review article: immediate-release proton-pump inhibitory therapy-potential advantages. Aliment. Pharmacol. Ther (2005) 22(suppl 3):25-30.
51. SCARPIGNATO C, PELOSINI I, DIMARIO F: Acid suppression therapy: where do we go from here? Dig. Dis. Sci. (2006) 24:11-46.
52. MILLER LG, JANKOVIC J: Metoclopramide-induced movement disorders. Arch. Intern. Med. (1989) 149:2486-2492.
53. WYSOWSKI DK, BACSANYI J: Cisapride and fatal arrthymia [letter]. New Engl. J. Med. (1996) 335:290.
54. ZHANG Q, LEHMANN A, RIGDA R et al.: Control of transient lower oesophageal sphincter relaxations and reflux by GABA (B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut (2002) 50:19-24.
55. CANGE L, JOHNSSON E, RHYDOLM H et al.: Baclofen-mediated gastro-oesophageal reflux control in patients with established reflux disease. Aliment. Pharmacol. Ther. (2002) 16:869-873.
56. KAHRILAS PJ, QUIGLEY EM, CASTELL DO et al.: The effects of regaserod (HFT 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (2000) 14:1503-1509.
57. GALMICHE JP, SHI G, SIMON B et al.: On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment. Pharmacol. Ther. (1998) 12:909-917.
58. WILHELMSEN I, HATLEBAKK JG, OLAFSSON S et al.: On demand therapy for reflux oesophagitis - a prospective study of symptoms, patient satisfaction and quality of life. Aliment. Pharmacol. Ther. (1999) 13:1035-1040.
59. BARDHAN KD, MULLER-LISSNER S, GIBARD MA et al.: Symptomatic gastroesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. Br. Med. J. (1999) 318:502-507.
60. HETZEL DJ, DENT J, REED WD et al.: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 95:903-912.
61. VIGNERI S, TERMINI R, LEANDRO G et al.: A comparison of five maintenance therapies for reflux esophagitis. New Engl. J. Med. (1995) 333:1106-1110.
62. ROBINSON M, LANZA F, AVNER D, HABER M: Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized double blind placebo-controlled trial. Ann. Intern. Med. (1996) 124:859-867.
63. KLINKENBERG-KNOL EC, NELIS F, DENT J et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology (2000) 118:661-669.
64. HATLEBAKK JG, KATZ PO, KUO B et al.: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment. Pharmacol. Ther. (1998) 12:1235-1240.
65. JACKSON PG, CLEIBER MA, ASKARI R et al.: Predictors of outcome in 100 consecutive laparoscopic antireflux procedures. Am. J. Surg. (2001) 181:231-235.
66. FRESTON JW. Omeprazole, hypergastrinemia and gastric carcinoid tumors. Ann. Intern. Med. (1994) 121:232-233.
67. LAHEIJ RJ, STURKENBOOM MC, HASSING RJ et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA (2003) 292:1955-1960.
68. DIAL S, DELANEY JA, BARKUN AN, SUISSA S: Use of gastric acid-suppressive agents and the risk of community-acquired clostridium difficile-associated disease. JAMA (2005) 294:2989-2995.
69. KUIPERS EJ, LUNDELL L, KLINKENBERG-KNOL EC et al.: Atrophic gastritis and Helicobacter pylori infection in patients with feflux esophagitis treated with omeprazole or fundoplication. New Engl. J. Med. (1996) 334:1018-1022.
70. MARCUARD SP, ALBERNAZ L, KHAZANIE PG: Omeprazole therapy causes malabsorption of cyanocobalamin. Ann. Intern. Med (1994) 120:211-215.
71. LAINE L, AHNEN D, MCCLAIN C et al.: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther (2000) 14:651-668.
72. LARSON JD, PATATANIAN E, MINER PB et al.: Double-blind placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet. Gynecol. (1997) 90:83-87.
73. KATZ PO, CASTELL DO: Gastroesophageal reflux disease during pregnancy. Gastroenterol. Clin. North Am. (1998) 27:153-167.
74. NIKFAR S, ABDOLLAHI M, MORETTI ME et al.: Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig. Dis. Sci (2002) 47:1526-1529.
75. DEVAULT KR, CASTELL DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol. (2005) 100:190-200.
76. DENT J, BRUN J, FENDRICK AM et al.: An evidence-based appraisal of reflux disease management: the Genval workshop report. Gut (1999) 44(Suppl. 2):S1.
77. SRINIVASAN R, VELA MF, KATZ PO et al.: Esophageal function testing using multichannel intraluminal impedance. Am. J. Physiol. (2001) 280:G457-62.